H
Helen Parise
Researcher at Yale University
Publications - 51
Citations - 8116
Helen Parise is an academic researcher from Yale University. The author has contributed to research in topics: Myocardial infarction & Percutaneous coronary intervention. The author has an hindex of 29, co-authored 51 publications receiving 7298 citations. Previous affiliations of Helen Parise include Columbia University & Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
A Prospective Natural-History Study of Coronary Atherosclerosis
Gregg W. Stone,Akiko Maehara,Alexandra J. Lansky,Bernard De Bruyne,Ecaterina Cristea,Gary S. Mintz,Roxana Mehran,John A. McPherson,Naim Farhat,Steven P. Marso,Helen Parise,Barry Templin,Roseann White,Zhen Zhang,Patrick W. Serruys +14 more
TL;DR: In patients who presented with an acute coronary syndrome and underwent percutaneous coronary intervention, major adverse cardiovascular events occurring during follow-up were equally attributable to recurrence at the site of culprit lesions and to nonculprit lesions.
Journal ArticleDOI
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study
Gregg W. Stone,Bernhard Witzenbichler,Giora Weisz,Michael Rinaldi,Franz-Josef Neumann,D. Christopher Metzger,Timothy D. Henry,David A. Cox,Peter L. Duffy,Ernest L. Mazzaferri,Paul A. Gurbel,Ke Xu,Helen Parise,Ajay J. Kirtane,Bruce R. Brodie,Roxana Mehran,Thomas Stuckey +16 more
TL;DR: The findings from this study emphasise the counter-balancing effects of haemorrhagic and ischaemic complications after stent implantation, and suggest that safer drugs or tailored strategies for the use of more potent agents must be developed if the benefits of greater platelet inhibition in patients with cardiovascular disease are to be realised.
Journal ArticleDOI
A risk score to predict bleeding in patients with acute coronary syndromes.
Roxana Mehran,Stuart J. Pocock,Eugenia Nikolsky,Tim Clayton,George Dangas,Ajay J. Kirtane,Helen Parise,Martin Fahy,Steven V. Manoukian,Frederick Feit,Magnus Ohman,Bernard Witzenbichler,Giulio Guagliumi,Alexandra J. Lansky,Gregg W. Stone +14 more
TL;DR: A simple risk score based on 6 baseline measures plus anticoagulation regimen identifies patients at increased risk for non-CABG-related bleeding and subsequent 1-year mortality, for whom appropriate treatment strategies can be implemented.
Journal ArticleDOI
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.
Gregg W. Stone,Bernhard Witzenbichler,Giulio Guagliumi,Jan Z. Peruga,Bruce R. Brodie,Dariusz Dudek,Ran Kornowski,Franz Hartmann,Bernard J. Gersh,Stuart J. Pocock,George Dangas,S. Chiu Wong,Martin Fahy,Helen Parise,Roxana Mehran +14 more
TL;DR: The effectiveness and safety of bivalirudin monotherapy and paclitaxel-eluting stenting are sustained at 3 years for patients with STEMI undergoing primary percutaneous coronary intervention.
Journal ArticleDOI
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Roxana Mehran,Alexandra J. Lansky,Bernhard Witzenbichler,Giulio Guagliumi,Jan Z. Peruga,Bruce R. Brodie,Dariusz Dudek,Ran Kornowski,Franz Hartmann,Bernard J. Gersh,Stuart J. Pocock,S. Chiu Wong,Eugenia Nikolsky,Louise Gambone,Lynn Vandertie,Helen Parise,George Dangas,Gregg W. Stone +17 more
TL;DR: In patients with STEMI undergoing primary PCI, anticoagulation with bivalirudin reduced the rates of net adverse clinical events and major bleeding at 1 year compared with treatment with heparin plus a GPI.